Selected data models

You must log in to select data models for download or further analysis.

71 Search results.
Relevance Rating New first Old first

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Laboratory Tests - Haematology; Blood Chemistry; Urinalysis

- 4/21/21 - 1 form, 4 itemgroups, 28 items, 1 language
Itemgroups: Administrative, Laboratory Tests - Haematology, Laboratory Tests - Blood Chemistry, Laboratory Tests - Urinalysis
Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Eligibility Criteria

- 4/20/21 - 1 form, 5 itemgroups, 27 items, 1 language
Itemgroups: Administrative, Inclusion Criteria, Exclusion Criteria, Inclusion/ Exclusion, Investigator's Signature
Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Screening - Toxicities Related to Previous Radiotherapy for SCLC; 12-Lead Electrocardiogram; Diagnostic Studies for Tumor Assessment; Ongoing Medical Conditions Associated with SCLC; Significant Medical/Surgical History and Physical Examination

- 4/17/21 - 1 form, 9 itemgroups, 20 items, 1 language
Itemgroups: Administrative, Toxicities related to previous Radiotherapy for SCLC, Toxicities related to previous Radiotherapy for SCLC, 12-Lead Electrocardiogram, Diagnostic Studies for Tumor Assessment, Ongoing Medical Conditions Associated with SCLC, Ongoing Medical Conditions Associated with SCLC, Significant Medical/ Surgical History and Physical Examination, Significant Medical/ Surgical History and Physical Examination
Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Day 1 Pre-Dose -Vital Signs; Pharmacogenetic Research Consent/ Blood Sample Collection; Investigational Product Compliance (Pazopanib); Investigational Product (First Dose); Biomarker Samples

- 5/16/19 - 1 form, 6 itemgroups, 30 items, 1 language
Itemgroups: Date of visit/ assessment, Vital Signs, Pharmacogenetic Research Consent/ Blood Sample Collection, Investigational Product Compliance - Pazopanib, Investigational Product - First Dose, Biomarker Sample
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Lung Cancer NCT00863512 Pre-Study - CALGB 30506 Pre-Study/Surgical Resection Form - 2821782v1.0 - CALGB 30506 Pre-Study/Surgical Resection Form

- 9/20/21 - 1 form, 9 itemgroups, 46 items, 1 language
Itemgroups: Header Module, Header, Initial Laboratory Values, Smoking Status, Pre-surgical Disease Status, Surgical Disease Status, Planned Treatment, Contact Information, Footer Module
CALGB 30506 Pre-Study/Surgical Resection Form Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5FE8C8A3-6705-BC07-E040-BB89AD4332A8

Lung Cancer NCT00096265 Demographic - A5 RTOG Phase III - Multiple Brain Mets Demographic Data Form - version 2 - 2277657v3.0 - A5 RTOG Phase III - Multiple Brain Mets Demographic Data Form - version 2

- 1/9/15 - 1 form, 4 itemgroups, 41 items, 1 language
Itemgroups: Header, Module 1, Module 2, Family History
A5 RTOG Phase III - Multiple Brain Mets Demographic Data Form - version 2 Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D81B5AB0-2D5B-616A-E034-0003BA12F5E7

dbGaP phs000907 Brain Metastases in Squamous Cell Lung Cancers - Eligibility

- 4/6/24 - 5 forms, 1 itemgroup, 1 item, 1 language
Itemgroup: IG.elig
Principal Investigator: Paul K. Paik, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA MeSH: Squamous Cell Carcinoma,Nonsmall Cell Lung Cancer https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000907 Putative oncogenic pathways in squamous cell lung cancer have been recently characterized, although their biologic repercussions in patients is largely unknown. This study sought to discover potential clinical manifestations of major pathways in squamous cell lung cancer, particularly the PI3K pathway. Two key findings emerged: patients with stage IV squamous cell lung cancer whose tumors harbored upstream PI3K aberrations had significantly worse survival and a higher burden of metastatic disease. In addition, brain metastases were significantly more common in these patients than in others. Paired lung primary/brain metastasis genotyping, including RNA sequencing and whole exome sequencing, uncovered a high degree of genetic heterogeneity between lung/brain pairs, and identified potential regulators of the metastatic process to brain.

pht004695.v1.p1

1 itemgroup 5 items

pht004696.v1.p1

1 itemgroup 5 items

pht004697.v1.p1

1 itemgroup 6 items

pht004698.v1.p1

1 itemgroup 12 items

dbGaP phs000488 Genomic Sequencing of Lung Adenocarcinoma - Eligibility

- 12/13/22 - 5 forms, 1 itemgroup, 1 item, 1 language
Itemgroup: IG.elig
Principal Investigator: Matthew Meyerson, MD, PhD, Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000488 Lung carcinoma is the leading cause of cancer death in the United States and world-wide; lung adenocarcinoma is the most common cause of lung cancer. Pilot studies of lung adenocarcinoma with hybrid-capture based whole exome sequencing will enable us to identify new targets for therapy and improve diagnosis. We will analyze a blend of whole exome and whole genome sequencing data as well as copy number and somatic mutation calls for 200 tumor and matched normal controls. When completed this study will represent the most comprehensive lung adenocarcinoma genome dataset to date.

pht002911.v2.p1

1 itemgroup 10 items

pht002912.v2.p1

1 itemgroup 5 items

pht002909.v2.p1

1 itemgroup 2 items

pht002910.v2.p1

1 itemgroup 3 items

Eligibility Carcinoma, Non-Small-Cell Lung NCT00425022

- 11/13/17 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
VATS Lobectomy for Clinical Stage IB or II Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00425022

Eligibility Carcinoma, Non-Small-Cell Lung NCT00791336

- 11/15/17 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00791336

Eligibility Carcinoma, Non-small Cell Lung NCT00093132

- 7/21/16 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT00093132

Eligibility Carcinoma, Non-Small-Cell Lung NCT00979576

- 11/17/17 - 1 form, 2 itemgroups, 48 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00979576

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial